NCT01931306Approved For Marketing不适用
An Open Label Expanded Access Program of Afatinib (BIBW 2992) in Treatment-naive or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 试验地点
- 8
研究概览
简要总结
To provide expanded access and to evaluate the safety, tolerability and efficacy of afatinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring Epidermal Growth Factor Receptor (EGFR) mutation(s) and have never been treated with an EGFR tyrosine kinase inhibitor (TKI)
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (8)
Loading locations...
相似试验
Approved For Marketing
不适用
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast CancerNeoplasms, BreastNCT00338247Novartis
已完成
3 期
Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) MutationsCarcinoma, Non-Small-Cell LungNCT02044380Boehringer Ingelheim14
已完成
2 期
Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast CancerBreast NeoplasmsNCT01325428Boehringer Ingelheim26
Approved For Marketing
不适用
Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (EAP)Idiopathic Pulmonary FibrosisNCT02171156Boehringer Ingelheim
No Longer Available
不适用
Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisNCT02230982Boehringer Ingelheim